{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:58:18Z","timestamp":1792699098023,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":2055,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\u2003<\/jats:title>\n                    <jats:p>In X-linked hypophosphatemia (XLH), inherited loss-of-function mutations in the PHEX gene cause excess circulating levels of fibroblast growth factor 23 (FGF23), leading to lifelong renal phosphate wasting and hypophosphatemia. Adults with XLH present with chronic musculoskeletal pain and stiffness, short stature, lower limb deformities, fractures, and pseudofractures due to osteomalacia, accelerated osteoarthritis, dental abscesses, and enthesopathy. Burosumab, a fully human monoclonal antibody, binds and inhibits FGF23 to correct hypophosphatemia. This report summarizes results from a double-blind, placebo-controlled, phase 3 trial of burosumab in symptomatic adults with XLH. Participants with hypophosphatemia and pain were assigned 1:1 to burosumab 1\u2009mg\/kg (n\u2009=\u200968) or placebo (n\u2009=\u200966) subcutaneously every 4 weeks (Q4W) and were comparable at baseline. Across midpoints of dosing intervals, 94.1% of burosumab-treated participants attained mean serum phosphate concentration above the lower limit of normal compared with 7.6% of those receiving placebo (p &amp;lt; 0.001). Burosumab significantly reduced the Western Ontario and the McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale compared with placebo (least squares [LS] mean\u2009\u00b1\u2009standard error [SE] difference, \u20138.1\u2009\u00b1\u20093.24; p\u2009=\u20090.012). Reductions in WOMAC physical function subscale (\u20134.9\u2009\u00b1\u20092.48; p\u2009=\u20090.048) and Brief Pain Inventory worst pain (\u20130.5\u2009\u00b1\u20090.28; p\u2009=\u20090.092) did not achieve statistical significance after Hochberg multiplicity adjustment. At week 24, 43.1% (burosumab) and 7.7% (placebo) of baseline active fractures were fully healed; the odds of healed fracture in the burosumab group was 16.8-fold greater than that in the placebo group (p &amp;lt; 0.001). Biochemical markers of bone formation and resorption increased significantly from baseline with burosumab treatment compared with placebo. The safety profile of burosumab was similar to placebo. There were no treatment-related serious adverse events or meaningful changes from baseline in serum or urine calcium, intact parathyroid hormone, or nephrocalcinosis. These data support the conclusion that burosumab is a novel therapeutic addressing an important medical need in adults with XLH.\u00a9 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jbmr.3475","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T02:01:42Z","timestamp":1530064902000},"page":"1383-1393","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":332,"title":["A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis"],"prefix":"10.1093","volume":"33","author":[{"given":"Karl L","family":"Insogna","sequence":"first","affiliation":[{"name":"Yale School of MedicineNew HavenCTUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Briot","sequence":"additional","affiliation":[{"name":"Centre d'Evaluation des Maladies OsseusesH\u00f4pital CochinParisFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A","family":"Imel","sequence":"additional","affiliation":[{"name":"Indiana University School of MedicineIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kamenick\u00fd","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-SudLe Kremlin Bic\u00eatreFrance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary D","family":"Ruppe","sequence":"additional","affiliation":[{"name":"Houston Methodist HospitalHoustonTXUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A","family":"Portale","sequence":"additional","affiliation":[{"name":"University of CaliforniaSan FranciscoCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weber","sequence":"additional","affiliation":[{"name":"Duke University Medical CenterDurhamNCUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pisit","family":"Pitukcheewanont","sequence":"additional","affiliation":[{"name":"Children's Hospital Los AngelesUniversity of Southern California Keck School of MedicineLos AngelesCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Il","family":"Cheong","sequence":"additional","affiliation":[{"name":"Seoul National University Children's HospitalSeoulSouth Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Jan de Beur","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of MedicineBaltimoreMDUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Imanishi","sequence":"additional","affiliation":[{"name":"Osaka City University Graduate School of MedicineOsakaJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ito","sequence":"additional","affiliation":[{"name":"University of Tokyo HospitalTokyoJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin H","family":"Lachmann","sequence":"additional","affiliation":[{"name":"University College London HospitalsLondonUK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Okayama Saiseikai General HospitalOkayamaJapan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Perwad","sequence":"additional","affiliation":[{"name":"University of CaliforniaSan FranciscoCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc.NovatoCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Yin","family":"Chen","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc.NovatoCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Theodore-Oklota","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc.NovatoCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Mealiffe","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc.NovatoCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"San Martin","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc.NovatoCAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O","family":"Carpenter","sequence":"additional","affiliation":[{"name":"Yale School of MedicineNew HavenCTUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the AXLES 1 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"issue":"2","key":"2024021014324578200_jbmr3475-bib-0001","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ng1095-130","article-title":"A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium","volume":"11","year":"1995","journal-title":"Nat Genet"},{"issue":"17","key":"2024021014324578200_jbmr3475-bib-0002","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"2024021014324578200_jbmr3475-bib-0003","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1681\/ASN.2007010068","article-title":"How fibroblast growth factor 23 works","volume":"18","author":"Liu","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2024021014324578200_jbmr3475-bib-0004","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00467-012-2309-3","article-title":"FGF23 production by osteocytes","volume":"28","author":"Bonewald","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"2024021014324578200_jbmr3475-bib-0005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024021014324578200_jbmr3475-bib-0006","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00247-012-2532-x","article-title":"Rickets: part I","volume":"43","author":"Shore","year":"2013","journal-title":"Pediatr Radiol"},{"issue":"1","key":"2024021014324578200_jbmr3475-bib-0007","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"issue":"2","key":"2024021014324578200_jbmr3475-bib-0008","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1148\/radiology.171.2.2539609","article-title":"X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features","volume":"171","author":"Hardy","year":"1989","journal-title":"Radiology"},{"issue":"6","key":"2024021014324578200_jbmr3475-bib-0009","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00005792-198911000-00002","article-title":"X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults","volume":"68","author":"Reid","year":"1989","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"2024021014324578200_jbmr3475-bib-0010","doi-asserted-by":"crossref","first-page":"E1492","DOI":"10.1210\/jc.2012-1336","article-title":"Abnormalities in muscle density and muscle function in hypophosphatemic rickets","volume":"97","author":"Veilleux","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024021014324578200_jbmr3475-bib-0011","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2024021014324578200_jbmr3475-bib-0012","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024021014324578200_jbmr3475-bib-0013","first-page":"879","article-title":"A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets","volume":"75","author":"Sullivan","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"26","key":"2024021014324578200_jbmr3475-bib-0014","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1056\/NEJM199112263252604","article-title":"Effects of therapy in X-linked hypophosphatemic rickets","volume":"325","author":"Verge","year":"1991","journal-title":"N Engl J Med"},{"issue":"4","key":"2024021014324578200_jbmr3475-bib-0015","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.2009-1671","article-title":"Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations","volume":"95","author":"Imel","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024021014324578200_jbmr3475-bib-0016","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"issue":"7","key":"2024021014324578200_jbmr3475-bib-0017","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2024021014324578200_jbmr3475-bib-0018","author":"Ruppe"},{"issue":"2","key":"2024021014324578200_jbmr3475-bib-0019","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","article-title":"Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases","volume":"17","author":"Daut","year":"1983","journal-title":"Pain"},{"key":"2024021014324578200_jbmr3475-bib-0020","author":"Bellamy"},{"issue":"1","key":"2024021014324578200_jbmr3475-bib-0021","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"2024021014324578200_jbmr3475-bib-0022","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1096\/fj.201600473R","article-title":"Hypophosphatemia promotes lower rates of muscle ATP synthesis","volume":"30","author":"Pesta","year":"2016","journal-title":"FASEB.J"},{"issue":"6","key":"2024021014324578200_jbmr3475-bib-0023","first-page":"1514","article-title":"Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets","volume":"75","author":"Rivkees","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024021014324578200_jbmr3475-bib-0024","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00860736","article-title":"Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease","volume":"9","author":"Taylor","year":"1995","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"2024021014324578200_jbmr3475-bib-0025","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1210\/jc.2010-0589","article-title":"Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status","volume":"95","author":"Carpenter","year":"2010","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/8\/1383\/56650644\/jbmr3475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/8\/1383\/56650644\/jbmr3475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T11:01:58Z","timestamp":1710327718000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/33\/8\/1383-1393\/7605352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,6,26]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3475","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8,1]]},"published":{"date-parts":[[2018,6,26]]},"assertion":[{"value":"2018-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}